EDGAR Filing Documents for 0001558370-23-015842

Form 8-K - Current report:

SEC Accession No. 0001558370-23-015842

Filing Date

2023-09-18

Accepted

2023-09-18 08:35:23

Documents

Period of Report

2023-09-15

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	enfn-20230915x8k.htm iXBRL	8-K	51904
2	EX-10.1	enfn-20230915xex10d1.htm	EX-10.1	1377828
3	EX-99.1	enfn-20230915xex99d1.htm	EX-99.1	7427
4	GRAPHIC	enfn-20230915xex99d1001.jpg	GRAPHIC	3300
	Complete submission text file	0001558370-23-015842.txt		1796763

Data Files

Seq	Description	Document	Type	Size
5	EX-101.SCH	enfn-20230915.xsd	EX-101.SCH	3120
6	EX-101.LAB	enfn-20230915_lab.xml	EX-101.LAB	16578
7	EX-101.PRE	enfn-20230915_pre.xml	EX-101.PRE	10711
9	EXTRACTED XBRL INSTANCE DOCUMENT	enfn-20230915x8k_htm.xml	XML	5062

Mailing Address 125 SOUTH CLARK STREET, SUITE 750 CHICAGO IL 60603

Business Address 125 SOUTH CLARK STREET, SUITE 750 CHICAGO IL 60603 (312) 253-9800

Enfusion, Inc. (Filer) CIK: 0001868912 (see all company filings)